BioSpace News Archive

Sermonix Pharmaceuticals today shared the results of EQUALS 2 (ESR1 QUAlity of Life Survey 2), a survey on the vaginal and sexual health of patients with ER+/HER2- metastatic breast cancer.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, today announced it will host an Investor Day at the Nasdaq in New York City on Tuesday, October 17, 2023.

The Bladder Cancer Advocacy Network announced its exclusive partnership with Ferring Pharmaceuticals as the National Presenting Sponsor for its 2024 Walks to End Bladder Cancer.

SCHOTT, the international technology group and inventor of specialty glass, was among the winners of the Pharma Innovation Award for its SCHOTT TOPPAC® freeze prefillable polymer syringes.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the submission of the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, as a companion diagnostic (CDx) assay for patients with muscle-invasive bladder cancer (MIBC).

Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved RivflozaTM (nedosiran) injection 80 mg, 128 mg, or 160 mg, a once-monthly subcutaneous ribonucleic acid interference (RNAi) therapy, to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.

Envoy Medical to Begin Trading October 2nd on NASDAQ with Ticker COCH

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.

Aviv Clinics, one of the world’s most advanced brain clinics, shares the results of a new case report showing a unique hyperbaric oxygen therapy (HBOT) protocol was effective for improving hand motor function in a chronic post-stroke patient.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided an update on its clinical portfolio at the company’s R&D Day.